These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 3592408)
1. Pulmonary natural killer cell activity is reduced in patients with bronchogenic carcinoma. Weissler JC; Nicod LP; Toews GB Am Rev Respir Dis; 1987 Jun; 135(6):1353-7. PubMed ID: 3592408 [TBL] [Abstract][Full Text] [Related]
2. Lung natural killer and interleukin-2 activity in lung cancer. A pulmonary compartment of augmented natural killer activity occurs in patients with bronchogenic carcinoma. Pitchenik AE; Guffee J; Stein-Streilein J Am Rev Respir Dis; 1987 Dec; 136(6):1327-32. PubMed ID: 3500659 [TBL] [Abstract][Full Text] [Related]
3. Phenotype and function of natural killer cells in patients with bronchogenic carcinoma. LeFever AV; Funahashi A Cancer Res; 1991 Oct; 51(20):5596-601. PubMed ID: 1655257 [TBL] [Abstract][Full Text] [Related]
8. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ. Lala PK; Parhar RS Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954 [TBL] [Abstract][Full Text] [Related]
9. Comparison between young and old patients with bronchogenic carcinoma. Prasad R; Verma SK; J Cancer Res Ther; 2009; 5(1):31-5. PubMed ID: 19293486 [TBL] [Abstract][Full Text] [Related]
10. Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibers but can be restored by recombinant interleukin-2. Robinson BW Am Rev Respir Dis; 1989 Apr; 139(4):897-901. PubMed ID: 2784645 [TBL] [Abstract][Full Text] [Related]
11. Tissue polypeptide antigen in bronchogenic carcinoma. Zatloukal P; Glagolicová A; Linhart M; Sebes A; Hencl P; Mĕricka O Neoplasma; 1993; 40(5):301-3. PubMed ID: 8272159 [TBL] [Abstract][Full Text] [Related]
12. A morphometric study of pulmonary cancer. Gerstl B; Switzer P; Yesner R Cancer Res; 1974 Jan; 34(1):248-54. PubMed ID: 4588547 [No Abstract] [Full Text] [Related]
13. Cytotoxic cell function in bronchogenic carcinoma. Kratikanont P; deShazo RD; Banks DE; Chapman Y Chest; 1987 Jul; 92(1):90-4. PubMed ID: 3595254 [TBL] [Abstract][Full Text] [Related]
14. Spontaneous lymphokine activated killer (LAK) activity in bronchoalveolar lavage cells from patients with bronchogenic carcinoma. Stein-Streilein J; Guffee J; Ramos M; Pitchenik AE Reg Immunol; 1989; 2(6):370-5. PubMed ID: 2485685 [TBL] [Abstract][Full Text] [Related]
15. [Immunologic evaluation in patients with lung cancer with special regard to peripheral blood natural killer cell activity and interleukin-2 productivity]. Matsuse T; Fukuchi Y; Nagase T; Suruda T; Yamaoka M; Ishida K; Harada N; Toba K; Orimo H Nihon Ronen Igakkai Zasshi; 1989 Sep; 26(5):475-80. PubMed ID: 2515327 [TBL] [Abstract][Full Text] [Related]
16. Changes in T cell population in patients with bronchogenic carcinoma. Shirakusa T; Shigematsu N; Yoshida T; Saito R; Katayama N; Inokuchi K J Thorac Cardiovasc Surg; 1978 Aug; 76(2):262-5. PubMed ID: 308122 [TBL] [Abstract][Full Text] [Related]
18. The histology of gonadotropin-secreting bronchogenic carcinoma. Cottrell JC; Becker KL; Matthews MJ; Moore C Am J Clin Pathol; 1969 Dec; 52(6):720-5. PubMed ID: 5353840 [No Abstract] [Full Text] [Related]
19. Lysis of fresh human tumor cells by autologous large granular lymphocytes and T-lymphocytes: two distinct killing activities induced by coculture with autologous tumor. Uchida A; Moore M J Natl Cancer Inst; 1984 Dec; 73(6):1285-92. PubMed ID: 6239944 [TBL] [Abstract][Full Text] [Related]
20. Pulmonary alveolar macrophage chemotaxis in malignant tumors of the lung. Renoux G; Lemarie E; Legrand MF; Renoux M; Lavandier M Adv Exp Med Biol; 1982; 155():361-7. PubMed ID: 6297267 [No Abstract] [Full Text] [Related] [Next] [New Search]